Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Justet (Paris , France), D. Klay (Utrecht, Netherlands), V. Cottin (Lyon, France), M. Molina Molina (Barcelona, Spain), H. Nunes (Bobigny, France), M. Reynaud-Gaubert (Marseille, France), J. Naccache (Paris , France), E. Manali (Athens, Greece), A. Froidure (Bruxelles, France), S. Jouneau ( Rennes, Belgium), L. Wemeau (Lille, France), C. Andrejak (Amiens , France), A. Gondouin (Besançon, France), S. Hirschi (Strasbourg, France), B. Bondue (Bruxelles , Belgium), P. Bonniaud (Dijon , France), C. Tromeur (Brest, France), G. Prevost (Toulouse, France), S. Marchand-Adam (Tours, France), M. Funke-Chambour (Bern, Switzerland), A. Gamez (Montpellier, France), C. Kanengiesser (Paris, France), C. Van Moorsel (Utrecht, Netherlands), B. Crestani (Paris, France), R. Borie (Paris , France). Tolerance and efficacy of antifibrotic treatments in IPF patients carriying telomere related gene mutations. 2140

Member's Comments

No comment yet.

Related content which might interest you: Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation Source: Eur Respir J, 57 (2) 2003198; 10.1183/13993003.03198-2020 Year: 2021 A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation Source: Eur Respir J, 51 (3) 1701875; 10.1183/13993003.01875-2017 Year: 2018 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Clinical outcomes after lung transplantation for fibrosis in telomerase related genes mutation carriers Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes Year: 2019 What influences patient choice of antifibrotic treatment in IPF? Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Assessment of blood biomarkers in patients with IPF under antifibrotic therapy Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 The influence of TNFα gene polymorphism on the therapeutic response in patients with sarcoidosis Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients? Source: Annual Congress 2007 - New drugs for asthma Year: 2007 The pharmacogenetic effect of ADRB2 polymorphisms on therapeutic response in COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018